Molecular Mechanisms Underlying Amyloid Beta Peptide Mediated Upregulation of Vascular Cell Adhesion Molecule-1 in Alzheimer Disease.

IF 3.1 3区 医学 Q2 PHARMACOLOGY & PHARMACY
Vrishali S Salian, Xiaojia Tang, Kevin J Thompson, Geoffry L Curan, Val J Lowe, Ling Li, Krishna R Kalari, Karunya K Kandimalla
{"title":"Molecular Mechanisms Underlying Amyloid Beta Peptide Mediated Upregulation of Vascular Cell Adhesion Molecule-1 in Alzheimer Disease.","authors":"Vrishali S Salian, Xiaojia Tang, Kevin J Thompson, Geoffry L Curan, Val J Lowe, Ling Li, Krishna R Kalari, Karunya K Kandimalla","doi":"10.1124/jpet.124.002280","DOIUrl":null,"url":null,"abstract":"<p><p>Amyloid <i>β</i>(A<i>β</i>) deposition and neurofibrillary tangles are widely considered the primary pathological hallmarks of familial and sporadic forms of Alzheimer disease (AD). However, cerebrovascular inflammation, which is prevalent in 70% of AD patients, is emerging as another core feature of AD pathology. In our current work, we investigated the hypothesis that A<i>β</i>42 exposure drives an increase in vascular cell adhesion molecule-1 (VCAM-1) expression, a cerebrovascular inflammatory marker expressed on the blood-brain barrier (BBB) endothelium in humans and murine models. We have demonstrated that the inflammation signaling pathway is upregulated in AD patient brains, and VCAM-1 expression is increased in AD patients compared with healthy controls. Furthermore, dynamic SPEC/CT imaging in APP,PS1 transgenic mice (a mouse model that overexpresses A<i>β</i>42) demonstrated VCAM-1 upregulation at the BBB. Although there is a strong association between A<i>β</i>42 exposure and an increase in VCAM-1 expression, the underlying mechanisms remain partially understood. Molecular mechanisms driving VCAM-1 expression at the BBB were investigated in polarized human cerebral microvascular endothelial cell monolayers. Moreover, by employing reverse-phase protein array assays and immunocytochemistry we demonstrated that A<i>β</i>42 increases VCAM-1 expression via the Src/p38/MEK signaling pathway. Therefore, targeting the Src/p38/MEK pathway may help modulate VCAM-1 expression at the BBB and help mitigate cerebrovascular inflammation in Alzheimer disease. SIGNIFICANCE STATEMENT: Although considered a core pathological feature of Alzheimer disease, molecular pathways leading to cerebrovascular inflammation remain only partially understood. Moreover, clinical diagnostic methods for detecting cerebrovascular inflammation are underdeveloped. This study demonstrated the detection of VCAM-1 using radio-iodinated VCAM-1 antibody and single-photon emission computed tomography/computed tomography imaging. Additionally, exposure to A<i>β</i>42 increases VCAM-1 expression on the blood-brain barrier endothelium via the Src/p38/MEK pathway. These findings are expected to aid in the development of diagnostic and therapeutic approaches for addressing cerebrovascular inflammation in AD.</p>","PeriodicalId":16798,"journal":{"name":"Journal of Pharmacology and Experimental Therapeutics","volume":" ","pages":"430-440"},"PeriodicalIF":3.1000,"publicationDate":"2024-11-19","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC11585316/pdf/","citationCount":"0","resultStr":null,"platform":"Semanticscholar","paperid":null,"PeriodicalName":"Journal of Pharmacology and Experimental Therapeutics","FirstCategoryId":"3","ListUrlMain":"https://doi.org/10.1124/jpet.124.002280","RegionNum":3,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"","PubModel":"","JCR":"Q2","JCRName":"PHARMACOLOGY & PHARMACY","Score":null,"Total":0}
引用次数: 0

Abstract

Amyloid β(Aβ) deposition and neurofibrillary tangles are widely considered the primary pathological hallmarks of familial and sporadic forms of Alzheimer disease (AD). However, cerebrovascular inflammation, which is prevalent in 70% of AD patients, is emerging as another core feature of AD pathology. In our current work, we investigated the hypothesis that Aβ42 exposure drives an increase in vascular cell adhesion molecule-1 (VCAM-1) expression, a cerebrovascular inflammatory marker expressed on the blood-brain barrier (BBB) endothelium in humans and murine models. We have demonstrated that the inflammation signaling pathway is upregulated in AD patient brains, and VCAM-1 expression is increased in AD patients compared with healthy controls. Furthermore, dynamic SPEC/CT imaging in APP,PS1 transgenic mice (a mouse model that overexpresses Aβ42) demonstrated VCAM-1 upregulation at the BBB. Although there is a strong association between Aβ42 exposure and an increase in VCAM-1 expression, the underlying mechanisms remain partially understood. Molecular mechanisms driving VCAM-1 expression at the BBB were investigated in polarized human cerebral microvascular endothelial cell monolayers. Moreover, by employing reverse-phase protein array assays and immunocytochemistry we demonstrated that Aβ42 increases VCAM-1 expression via the Src/p38/MEK signaling pathway. Therefore, targeting the Src/p38/MEK pathway may help modulate VCAM-1 expression at the BBB and help mitigate cerebrovascular inflammation in Alzheimer disease. SIGNIFICANCE STATEMENT: Although considered a core pathological feature of Alzheimer disease, molecular pathways leading to cerebrovascular inflammation remain only partially understood. Moreover, clinical diagnostic methods for detecting cerebrovascular inflammation are underdeveloped. This study demonstrated the detection of VCAM-1 using radio-iodinated VCAM-1 antibody and single-photon emission computed tomography/computed tomography imaging. Additionally, exposure to Aβ42 increases VCAM-1 expression on the blood-brain barrier endothelium via the Src/p38/MEK pathway. These findings are expected to aid in the development of diagnostic and therapeutic approaches for addressing cerebrovascular inflammation in AD.

阿尔茨海默病中淀粉样 beta 肽介导的血管细胞粘附分子-1 上调的分子机制。
淀粉样β(Aβ)沉积和神经纤维缠结被广泛认为是家族性和散发性阿尔茨海默病(AD)的主要病理特征。然而,在 70% 的阿尔茨海默病患者中普遍存在的脑血管炎症正在成为阿尔茨海默病病理的另一个核心特征。此外,在阿尔茨海默病患者中还观察到了炎症信号通路的激活;特别是,在阿尔茨海默病患者中发现脑血管炎症加剧。我们的研究表明,AD 患者大脑中的炎症信号通路被上调。此外,通过动态 SPEC/CT 成像检测发现,血脑屏障(BBB)内皮上表达的脑血管炎症标志物血管细胞粘附分子-1(VCAM-1)在 APP、PS1 小鼠(一种过量表达 Ab42 的小鼠模型)中上调。虽然 Aβ42 暴露与 VCAM-1 表达增加之间存在密切联系,但 Aβ42 对 VCAM-1 表达的影响机制仍未得到充分研究。因此,我们研究了Ab42暴露会增加人脑微血管内皮细胞(hCMEC/D3)单层中VCAM-1表达的假设。此外,反相蛋白阵列测定(RPPA)和免疫细胞化学证明,Ab42 通过 Src/p38/MEK 信号通路增加了 VCAM-1 的表达,特别是在血脑屏障(BBB)内皮细胞中。总之,这些结果表明,Ab42 通过 Src/MEK/p38 途径提高了 VCAM-1 的表达,从而加剧了脑血管炎症。因此,以 BBB 上的 VCAM-1 为靶点作为诊断和治疗标志物,可能会为检测和减轻阿尔茨海默病的脑血管炎症带来潜力。意义声明 虽然阿尔茨海默病被认为是一种核心病理特征,但导致脑血管炎症的分子途径仍不完全清楚。此外,检测脑血管炎症的临床诊断方法尚不完善。在这项研究中,我们利用放射性碘化 VCAM-1 抗体和 SPECT/CT 成像技术对 VCAM-1 进行了检测。研究表明,暴露于 Aβ42 会通过 Src/p38/MEK 通路增加 BBB 内皮上的 VCAM-1 表达。这些发现有望帮助开发诊断和治疗方法,以解决AD的脑血管炎症问题。
本文章由计算机程序翻译,如有差异,请以英文原文为准。
求助全文
约1分钟内获得全文 求助全文
来源期刊
CiteScore
6.90
自引率
0.00%
发文量
115
审稿时长
1 months
期刊介绍: A leading research journal in the field of pharmacology published since 1909, JPET provides broad coverage of all aspects of the interactions of chemicals with biological systems, including autonomic, behavioral, cardiovascular, cellular, clinical, developmental, gastrointestinal, immuno-, neuro-, pulmonary, and renal pharmacology, as well as analgesics, drug abuse, metabolism and disposition, chemotherapy, and toxicology.
×
引用
GB/T 7714-2015
复制
MLA
复制
APA
复制
导出至
BibTeX EndNote RefMan NoteFirst NoteExpress
×
提示
您的信息不完整,为了账户安全,请先补充。
现在去补充
×
提示
您因"违规操作"
具体请查看互助需知
我知道了
×
提示
确定
请完成安全验证×
copy
已复制链接
快去分享给好友吧!
我知道了
右上角分享
点击右上角分享
0
联系我们:info@booksci.cn Book学术提供免费学术资源搜索服务,方便国内外学者检索中英文文献。致力于提供最便捷和优质的服务体验。 Copyright © 2023 布克学术 All rights reserved.
京ICP备2023020795号-1
ghs 京公网安备 11010802042870号
Book学术文献互助
Book学术文献互助群
群 号:481959085
Book学术官方微信